PMID- 28182344
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20181023
IS  - 1433-6510 (Print)
IS  - 1433-6510 (Linking)
VI  - 63
IP  - 2
DP  - 2017 Feb 1
TI  - Clinical Implication of Cystatin C and beta2-Microglobulin in Early Detection of 
      Diabetic Nephropathy.
PG  - 241-247
LID - 10.7754/Clin.Lab.2016.160719 [doi]
AB  - BACKGROUND: Diabetic nephropathy (DN) is one of the major late complications of 
      type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the 
      efficiency of cystatin C (cysC) and beta2-microglobulin (beta2-MG) in diagnosing early 
      DN and to identify the optimal threshold in the Chinese patients. METHODS: T2DM 
      patients were divided into 102 non-DN subjects, 60 early DN subjects, and 38 
      clinical DN subjects. Blood and urine measurements were compared among the 
      groups. Receiver-operating characteristic (ROC) curves and areas under the curve 
      (AUC) were calculated to demonstrate the prediction values of the variables. 
      RESULTS: Stepwise regression analysis showed that the levels of cysC and beta2-MG 
      were associated with early DN. The AUC was 0.874 for cysC and 0.792 for beta2-MG. 
      The threshold based on the ROC curve had the best diagnostic performance compared 
      with the threshold with respect to mean + SD (standard deviation) and parallel 
      tests. A high sensitivity of 91.67% was achieved at the cysC threshold of 0.91 
      mg/L with a moderate specificity of 76.47% and a sensitivity of 80.00% for the 
      beta2-MG threshold of 1.86 mg/L with a specificity of 67.65%. CONCLUSIONS: The 
      findings suggest that the cysC threshold of 0.91 mg/L may be acceptable as a 
      diagnostic criterion for early DN in the Chinese patients. The results also 
      suggest that for T2DM patients the normal reference range of cysC should be set 
      lower in favor of early DN screening.
FAU - Chen, Hongmei
AU  - Chen H
FAU - Li, Hongbin
AU  - Li H
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Clin Lab
JT  - Clinical laboratory
JID - 9705611
RN  - 0 (Biomarkers)
RN  - 0 (CST3 protein, human)
RN  - 0 (Cystatin C)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Area Under Curve
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - China
MH  - Cross-Sectional Studies
MH  - Cystatin C/*analysis
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Nephropathies/blood/*diagnosis/etiology
MH  - Early Diagnosis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - ROC Curve
MH  - Reference Values
MH  - beta 2-Microglobulin/*blood
EDAT- 2017/02/10 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/02/10 06:00
PHST- 2017/02/10 06:00 [entrez]
PHST- 2017/02/10 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
AID - 10.7754/Clin.Lab.2016.160719 [doi]
PST - ppublish
SO  - Clin Lab. 2017 Feb 1;63(2):241-247. doi: 10.7754/Clin.Lab.2016.160719.